These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 781380)

  • 61. Plasma C3 and C4 concentrations in management of glomerulonephritis.
    Cameron JS; Vick RM; Ogg CS; Seymour WM; Chantler C; Turner DR
    Br Med J; 1973 Sep; 3(5882):668-72. PubMed ID: 4200478
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Inherited deficiencies of complement in man.
    Ray TL; Wuepper KD
    Int J Dermatol; 1977 Dec; 16(10):775-92. PubMed ID: 340392
    [No Abstract]   [Full Text] [Related]  

  • 63. In situ complement activation in porcine membranoproliferative glomerulonephritis type II.
    Jansen JH; Høgåsen K; Harboe M; Hovig T
    Kidney Int; 1998 Feb; 53(2):331-49. PubMed ID: 9461093
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Immune complex glomerulonephritis in C4- and C3-deficient mice.
    Quigg RJ; Lim A; Haas M; Alexander JJ; He C; Carroll MC
    Kidney Int; 1998 Feb; 53(2):320-30. PubMed ID: 9461092
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Atypical hypocomplementemic vasculitis syndrome in a child.
    Waldo FB; Leist PA; Strife CF; Forristal J; West CD
    J Pediatr; 1985 May; 106(5):745-50. PubMed ID: 2987470
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Complement profiles in acute post-streptococcal glomerulonephritis.
    Wyatt RJ; Forristal J; West CD; Sugimoto S; Curd JG
    Pediatr Nephrol; 1988 Apr; 2(2):219-23. PubMed ID: 3153014
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Serum immune complexes in membranoproliferative and other glomerulonephritides.
    Ooi YM; Vallota EH; West CD
    Kidney Int; 1977 Apr; 11(4):275-83. PubMed ID: 853604
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Membranoproliferative glomerulonephritis with isolated C3 deposits: case report and literature review.
    Darouich S; Goucha R; Jaafoura MH; Zekri S; Kheder A; Ben Maiz H
    Ultrastruct Pathol; 2011 Feb; 35(1):42-6. PubMed ID: 21265634
    [TBL] [Abstract][Full Text] [Related]  

  • 69. C3 nephritic factor (C3NeF): dissociation of cell-bound and fluid phase stabilization of alternative pathway C3 convertase.
    Ng YC; Peters DK
    Clin Exp Immunol; 1986 Aug; 65(2):450-7. PubMed ID: 3641695
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Glomerular localization of the early components of complement in glomerulonephritis].
    Barbiano di Belgiojoso G; Tarantino A; Durante A; Guerra L
    Minerva Nefrol; 1974; 21(3):169-78. PubMed ID: 4463297
    [No Abstract]   [Full Text] [Related]  

  • 71. Immunoglobulin A nephropathy.
    Zimmerman SW; Burkholder PM
    Arch Intern Med; 1975 Sep; 135(9):1217-23. PubMed ID: 1164123
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Specific measurement of alternate pathway activation of complement in human glomerulonephritides (GN): 125 cases (author's transl)].
    Berthoux FC; Freyria AM
    Nephrologie; 1980; 1(2):61-6. PubMed ID: 7301022
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Complement function and disorders.
    Kehoe JM
    Pediatr Ann; 1976 Jun; 5(6):397-404. PubMed ID: 1272620
    [No Abstract]   [Full Text] [Related]  

  • 74. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN.
    Iatropoulos P; Daina E; Curreri M; Piras R; Valoti E; Mele C; Bresin E; Gamba S; Alberti M; Breno M; Perna A; Bettoni S; Sabadini E; Murer L; Vivarelli M; Noris M; Remuzzi G; ;
    J Am Soc Nephrol; 2018 Jan; 29(1):283-294. PubMed ID: 29030465
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Membranoproliferative glomerulonephritis. One of many diesases?
    Jones DB
    Arch Pathol Lab Med; 1977 Sep; 101(9):457-61. PubMed ID: 142460
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The properdin pathway: mechanisms of complement activation and analogies to the classical pathway.
    Fearon DT; Austen KF; Ruddy S
    Rheumatology; 1975; 6():2-16. PubMed ID: 1105744
    [No Abstract]   [Full Text] [Related]  

  • 77. Studies of serum complement in the hypocomplementaemic nephritides.
    Williams DG; Peters DK; Fallows J; Petrie A; Kourilsky O; Morel-Maroger L; Cameron JS
    Clin Exp Immunol; 1974 Nov; 18(3):391-405. PubMed ID: 4219908
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Experimental models of membranoproliferative glomerulonephritis, including dense deposit disease.
    Vernon KA; Pickering MC; Cook T
    Contrib Nephrol; 2011; 169():198-210. PubMed ID: 21252520
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The effect of age on the character of immune complex disease: a comparison of the incidence and relative size of materials reactive with Clq in sera of patients with glomerulonephritis and cancer.
    Rossen RD; Reisberg MA; Singer D; Suki WN; Duffy J; Hersh EM; Schloeder FX; Hill LL; Eknoyan G
    Medicine (Baltimore); 1979 Jan; 58(1):65-79. PubMed ID: 154003
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Genetics of the complement system.
    Alper CA; Rosen FS
    Adv Hum Genet; 1976; 7():141-88. PubMed ID: 827931
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.